Repeated administration of berberine inhibits cytochromes P450 in humans

European Journal of Clinical Pharmacology

Volumn 68, Issue 2, 2012, Pages 213-217

  Guo, Ying ^a,b   Chen, Yao ^a   Tan, Zhi Rong ^a   Klaassen, Curtis D ^a,b   Zhou, Hong Hao ^a  

^a Central South University   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Berberine; CYP2C9; CYP2D6; CYP3A4; Humans

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; BERBERINE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; LOSARTAN; MIDAZOLAM; OMEPRAZOLE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG URINE LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; BERBERINE; CAFFEINE; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DRUG INTERACTIONS; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; HUMANS; LOSARTAN; MALE; MIDAZOLAM; OMEPRAZOLE; YOUNG ADULT;

EID: 84857049257     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1108-2     Document Type: Article

References (18)

1. PR Vuddanda S Chakraborty S Singh 2010 Berberine: a potential phytochemical with multispectrum therapeutic activities Expert Opin Investig Drugs 19 10 1297 1307 10.1517/13543784.2010.517745 20836620 10.1517/13543784. 2010.517745 1:CAS:528:DC%2BC3cXhtFCktbfP
2. PM Barnes B Bloom RL Nahin 2008 Complementary and alternative medicine use among adults and children: United States, 2007 Natl Health Stat Report 12 1 23 19361005
3. X Wu Q Li H Xin A Yu M Zhong 2005 Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study Eur J Clin Pharmacol 61 8 567 572 10.1007/s00228-005-0952- 3 16133554 10.1007/s00228-005-0952-3 1:CAS:528:DC%2BD2MXhtVKitrrO (Pubitemid 41414240)
4. AS Etheridge SR Black PR Patel J So JM Mathews 2007 An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents Planta Med 73 8 731 741 10.1055/s-2007-981550 17611934 10.1055/s-2007-981550 1:CAS:528:DC%2BD2sXoslSit7k%3D (Pubitemid 47234614)
5. A Gunes G Ozbey EH Vural C Uluoglu MG Scordo H Zengil ML Dahl 2009 Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population Pharmacogn 10 5 769 778 10.2217/pgs.09.22 10.2217/pgs.09.22 1:CAS:528:DC%2BD1MXmtVahsb4%3D
6. JY Ryu IS Song YE Sunwoo JH Shon KH Liu IJ Cha JG Shin 2007 Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo Clin Pharmacol Ther 82 5 531 540 10.1038/sj.clpt.6100187 17392720 10.1038/sj.clpt.6100187 1:CAS:528: DC%2BD2sXhtF2qsL7O (Pubitemid 47622519)
7. XP Chen ZR Tan SL Huang Z Huang DS Ou-Yang HH Zhou 2003 Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects Clin Pharmacol Ther 73 3 264 271 10.1067/mcp.2003.14 12621391 10.1067/mcp.2003.14 1:CAS:528:DC%2BD3sXitFagt7k%3D (Pubitemid 36269677)
8. J Zheng B Chen B Jiang L Zeng ZR Tang L Fan HH Zhou 2010 The effects of puerarin on CYP2D6 and CYP1A2 activities in vivo Arch Pharm Res 33 2 243 246 10.1007/s12272-010-0209-2 20195825 10.1007/s12272-010-0209-2 1:CAS:528:DC%2BC3cXis1ekt7g%3D
9. Z Li G Wang LS Wang W Zhang ZR Tan L Fan BL Chen Q Li J Liu JH Tu DL Hu ZQ Liu HH Zhou 2009 Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects Xenobiotica 39 10 788 793 10.1080/00498250903134435 19604036 10.1080/00498250903134435 1:CAS:528:DC%2BD1MXhtVOms77E
10. LS Wang G Zhou B Zhu J Wu JG Wang AM Abd El-Aty T Li J Liu TL Yang D Wang XY Zhong HH Zhou 2004 St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole Clin Pharmacol Ther 75 3 191 197 10.1016/j.clpt.2003.09.014 15001970 10.1016/j.clpt.2003.09.014 1:CAS:528:DC%2BD2cXhslenurs%3D (Pubitemid 38314868)
11. Y Chen P Xiao DS Ou-Yang L Fan D Guo YN Wang Y Han JH Tu G Zhou YF Huang HH Zhou 2009 Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers Clin Exp Pharmacol Physiol 36 8 828 833 10.1111/j.1440-1681.2009. 05158.x 19215233 10.1111/j.1440-1681.2009.05158.x 1:CAS:528:DC%2BD1MXpvFOgsLo%3D
12. JH Tu YJ He Y Chen L Fan W Zhang ZR Tan YF Huang D Guo DL Hu D Wang Z Hong-Hao 2010 Effect of glycyrrhizin on the activity of CYP3A enzyme in humans Eur J Clin Pharmacol 66 8 805 810 10.1007/s00228-010-0814-5 20393696 10.1007/s00228-010-0814-5 1:CAS:528:DC%2BC3cXptVaiurk%3D
13. S Ghassabian M Chetty BN Tattam MC Chem J Glen J Rahme Z Stankovic I Ramzan M Murray AJ McLachlan 2009 A high-throughput assay using liquid chromatography-tandem mass spectrometry for simultaneous in vivo phenotyping of 5 major cytochrome p450 enzymes in patients Ther Drug Monit 31 2 239 246 10.1097/FTD.0b013e318197e1bf 19307938 10.1097/FTD.0b013e318197e1bf 1:CAS:528:DC%2BD1MXjsFWqtr0%3D
14. U Yasar C Forslund-Bergengren G Tybring P Dorado A Llerena F Sjoqvist E Eliasson ML Dahl 2002 Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype Clin Pharmacol Ther 71 1 89 98 10.1067/mcp.2002.121216 11823761 10.1067/mcp.2002.121216 1:CAS:528: DC%2BD38XitFOgsLk%3D (Pubitemid 34124042)
15. CL Alfaro YW Lam J Simpson L Ereshefsky 1999 CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline J Clin Psychopharmacol 19 2 155 163 10211917 10.1097/00004714- 199904000-00011 1:CAS:528:DyaK1MXitlyhsLg%3D (Pubitemid 29161961)
16. LH Yang FE Lu H Dong LJ Xu KF Wang 2005 Effect of emodin and berberine on gastrointestinal motility in type 2 diabetic rats World Chin J Digestol 13 5 608 611 1:CAS:528:DC%2BD28Xjt1Oqt7g%3D (Pubitemid 40529602)
17. SM Huang JM Strong L Zhang KS Reynolds S Nallani R Temple S Abraham SA Habet RK Baweja GJ Burckart S Chung P Colangelo D Frucht MD Green P Hepp E Karnaukhova HS Ko JI Lee PJ Marroum JM Norden W Qiu A Rahman S Sobel T Stifano K Thummel XX Wei S Yasuda JH Zheng H Zhao LJ Lesko 2008 New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process J Clin Pharmacol 48 6 662 670 10.1177/0091270007312153 18378963 10.1177/0091270007312153 1:CAS:528: DC%2BD1cXns1Kitr4%3D (Pubitemid 351713150)
18. Guo Y, Li F, Ma XC, Cheng XG, Zhou HH, Klaassen CD (2011) CYP2D plays a major role in berberine metabolism in liver of mice and humans. Xenobiotica. doi: 10.3109/00498254.2011.597456